Ultrastructural localization of secretory type II phospholipase A2 in atherosclerotic and nonatherosclerotic regions of human arteries

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 4, 1998, Pages 519-525

  Romano, Mirtha ^a   Romano, Egidio ^a   Björkerud, Sören ^b   Hurt Camejo, Eva ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Atherosclerosis; Inflammation; Matrix; Phospholipase A2

Indexed keywords

PHOSPHOLIPASE A2;

ARTICLE; ATHEROSCLEROSIS; AUTOPSY; CELL ULTRASTRUCTURE; ELECTRON MICROSCOPY; ENZYME ACTIVITY; ENZYME LOCALIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOGOLD STAINING; IMMUNOHISTOCHEMISTRY; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; TISSUE DISTRIBUTION;

EID: 0031956684     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.4.519     Document Type: Article

References (18)

1. 2. J Biol Chem. 1994;269:13057-13060.
2. Serhan CN, Haeggström JZ, Leslie CC. Lipid mediator networks in cell signaling: update and impact of cytokines. FASEB J. 1996;10:1147-1158.
3. Moolenaar WH. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem. 1995;270:12949-12952.
4. Marcus AJ, Hajjar DP. Vascular transcellular signaling. J Lipid Res. 1993;34:2017-2031.
5. Evangelou AM. Platelet-activating factor (PAF): implications for coronary heart and vascular diseases. Prostaglandins Leukot Essent Fatty Acids. 1994;50:1-28.
6. Exton JH. Phosphatidylcholine breakdown and signal transduction. Biochim Biophys Acta. 1994;1212:26-42.
7. Esterbauer H, Gebicki HJ, Puhl H, Jürgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med. 1992;13:341-390.
8. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocyte and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805-2809.
9. McMurray HF, Parthasarathy S, Steinberg D. Oxidatively modified low density lipoprotein is a chemoattractant for human T lymphocytes. J Clin Invest. 1993;92:1004-1008.
10. 2 in T-lymphocyte activation: implication in propagation of inflammatory reaction. Proc Natl Acad Sci U S A. 1993;90:716-719.
11. Kume N, Gimbrone MA. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest. 1994;93:907-911.
12. Nakano T, Raines EW, Abraham JA, Klagsbrun M, Ross R. Lysophos-phatidylcholine upregulates the level of heparin-binding epidermal growth factor-like growth factor mRNA in human monocytes. Proc Natl Acad Sci U S A. 1994;91:1069-1073.
13. Murohara T, Scalia R, Lefer AM. Lysophosphatidylcholine promotes P-selectin Expression in platelets, and endothelial cells. Circ Res. 1996;78:780-789.
14. Stiko A, Regnström J, Shah PK, Cercek B, Nilsson J. Active oxygen species and lysophosphatidylcholine are involved in oxidized low density lipoprotein activation of smooth muscle cell DNA synthesis. Arterioscler Thromb Vasc Biol. 1996;16:194-200.
15. Chai Y-C, Howe PH, DiCorleto PE, Chisolm GM. Oxidized low density lipoprotein and lysophosphatidylcholine stimulate cell cycle entry in vascular smooth muscle cell. J Biol Chem. 1996;271:17791-17797.
16. Cowan CL, Steffen RP. Lysophosphatidylcholine inhibits relaxation of rabbit abdominal aorta mediated by endothelium-derived nitric oxide and endothelium-derived hyperpolarizing factor independent of protein kinase C activation. Arterioscler Thromb Vasc Biol. 1995;15:2290-2297.
17. Freeman J, Kuo W, Drenger B, Barnett T, Levine M, Flavahan N. Analysis of lysophosphatidylcholine-induced endothelial dysfunction. J Cardiovasc Pharmacol. 1996;28:345-352.
18. Murugesan G, Fox PL. Role of lysophosphatidylcholine in the inhibition of endothelial cell motility by oxidized low density lipoprotein. J Clin Invest. 1996;97:2736-2744.